Bochuang Bio Secures Tens of Millions RMB in Pre-A Financing to Advance Innovative Bio-Organized Functional Membranes

Recently, Bochuang Biotech (hereinafter referred to as "Bochuang Biotech") successfully completed a multi-million-yuan Pre-A round of financing. This round of financing was participated by several well-known investment institutions. Led by Beijing Huafang Investment Co., Ltd., and followed by TigerYeah Capital, BMC, and Suzhou Industrial Park Leader Venture Capital Co., Ltd. This marks the third round of financing for Bochuang Biotech in nearly two years.

Bochuang Biotech stated: It will make full use of this round of financing funds to further accelerate the R&D progress of its existing products such as artificial cornea and artificial bone membrane. At the same time, it will increase investment in R&D in the fields of collagen raw materials and electrochemical assembly technology for biological macromolecules, optimizing and supplementing the existing product line.

Bochuang Biotech was established in June 2022 as a national high-tech enterprise, a technology-oriented private enterprise in Jiangsu Province, and a leader in the Gusu and Industrial Park entrepreneurial talent programs. Its core technology originates from the team led by Academician Changsheng Liu. Leveraging the technical and talent advantages of its founding team, Bochuang Biotech will develop a series of high-end artificial corneas, periosteum, and other innovative products based on the internationally pioneering "Electrochemical Deposition of Biomacromolecules" (EDP) technology platform. The company is committed to advancing the upgrading of collagen repair products and membrane repair products in China. Core product: Collagen Artificial Cornea (E-Col), which, with its unique advantages of reducing host immune rejection, preventing the ingrowth of new blood vessels, and avoiding material clouding, maintains high transparency during its service life, significantly improving the success rate of corneal repair. It has currently entered the preclinical animal evaluation stage and is expected to begin clinical trials next year.

Bochuang Biotech was established in June 2022 as a national high-tech enterprise, a Jiangsu Province science and technology private enterprise, and a Gusu and Industrial Park entrepreneurial leading talent enterprise. Its core technology mainly originates from the team led by Academician Changsheng Liu. Leveraging the technical and talent advantages of its founding team, Bochuang Biotech will develop a series of high-end artificial corneas, periosteum, and other innovative products based on the internationally pioneering "biomacromolecule electrochemical deposition" EDP technology platform. The company is committed to promoting the upgrading of collagen repair products and membrane repair products in China. Core product: Collagen Artificial Cornea (E-Col), which, with its unique advantages of reducing host immune rejection, preventing the ingrowth of new blood vessels, and avoiding material clouding, maintains high transparency during its service life, thereby significantly improving the success rate of corneal repair. It has currently entered the preclinical animal evaluation stage and is expected to undergo clinical trials next year.

Dr. Wangqian Luo, Co-Founding Partner of Beijing Huafang Investment Co., Ltd., stated: The invention and application of new materials have always brought revolutionary changes to various fields of human society, including biomedicine. Bochuang Biotech, through its independently developed controllable electrochemical assembly technology, rearranges traditional collagen molecules in a controlled manner to form a new generation of membrane materials with entirely new functional properties. Based on different clinical and consumer demands, this technology can be used to develop a variety of innovative products, including artificial corneas and artificial skin, which far surpass the characteristics of existing materials, driving the generational leap of functional membrane materials for medical use in China. Relying on the successful experience of an academician-led team in technological innovation and commercial transformation, the company has efficiently advanced the rapid progress of several innovative product pipelines. We also look forward to this investment inspiring more creative collisions and technical product collaborations between Bochuang and the Huafang ecosystem companies, forming greater breakthroughs together to benefit more patients.

Dr. Ji Tianrong, founding partner of TigerYeah Capital, stated: Bochuang Biotech has an experienced and dynamic entrepreneurial team that combines years of R&D achievements with clinical applications to develop a new generation of bio-tissue functional membranes that stand out in functionality, have stable batch quality, and controllable costs. These innovations meet urgent clinical needs in fields such as ophthalmology and dentistry. We look forward to Bochuang rapidly launching its products to bring benefits to more patients.

Dr. Jiang Yongxiang, Managing Partner of BMC, stated: BMC has always adhered to the principles of "long-termism" and "value discovery and creation," and holds a very positive outlook on the development prospects of novel biomaterials in the field of regenerative medicine. Bochuang Biotech, based on years of technical accumulation by Academician Liu Changsheng and Professor Qu Xue’s team in the field of controllable electrochemical assembly deposition, has independently developed a series of regenerative products such as oral membranes and artificial corneas, which have broad market prospects. BMC is honored to be involved with a growth-potential sci-tech enterprise like Bochuang Biotech and is willing to continuously support the rapid development of the company, jointly contributing to the advancement of scientific innovation.

Tao Shanshan, head of the first department of Suzhou Industrial Park Leader Venture Capital, stated: Bochuang Biotech has developed a technology platform with fully independent intellectual property rights and possesses systematic capabilities for developing a new generation of bio-tissue functional membranes. The products have an extremely broad market prospect. We look forward to Bochuang accelerating the research and development progress of its products in the pipeline, contributing to the deep innovation of domestically produced medical devices in China.